Global market access

Value-based pricing and strategy

Develop pricing strategies that reflect the true value of your asset and gain insights to help you understand and quantify investment trade-offs.

 

Our expertise supports your pricing negations and includes:

  • Comprehensive assessments of the pricing and reimbursement landscape for your product through critical analysis of existing HTA and reimbursement decisions
  • Tailored research based on different endpoint scenarios to improve understanding of payer evidence requirements and support your value-based pricing and reimbursement strategy
  • Primary research through international advisory boards and interviews with payers and clinicians to understand real-world issues and decision-drivers.

It is critical to understand the scale and potential impact of high-cost and/or combination treatments coming to market, which can force significant changes in pricing and reimbursement policies; we can help you develop innovative pricing and contracting strategies to support the best outcomes for your asset.

 

Our consulting solutions include:

  • Evaluation of economically justifiable price
  • Payer pricing research
  • Innovative pricing and contracting strategy
  • Lifecycle management pricing strategy

 

These services are provided by Avalere, PAI, PRMA Consulting, and Skysis – part of Fishawack Health.

Request a call

Driving BioPharma Access in Europe: Insights for Markets Outside of EU5  

Welcoming Lewis Ruff, Senior Director, Global HEOR, within our policy, access, value, and evidence capability

Adapting to Change: Strategies for Pharma Service Providers, CROs, and R&D Partnerships in the Era of the Inflation Reduction Act

Forecasting global value assessments for a rare-disease drug

Welcoming Tyler Piazza, Partnerships Director, HEOR and hēRo3, within our policy, access, value, and evidence capability

Welcoming Caroline Solon, Senior Director Global Market Access, within our policy, access, value, and evidence capability

Cross-functional integrated evidence generation planning for a therapy treating ANCA‑associated vasculitis (AAV)

Digital therapeutics: policy, access, value, and evidence

The hēRo3 Revolution: Accelerating and Empowering HEOR Analytics with Cutting-Edge Digital Solutions

Value, Evidence, and Access: insights for markets outside of the EU5

Many thanks for supporting our launch. I really appreciate your flexibility with timing and study design to give us impactful and actionable next steps for our payer customers. We couldn’t have done it without your support. Job well done!

Payer Access Marketing Manager, top-5 pharmaceutical company.

You have a vision; we are the consulting partner that will get you there.
We would be delighted to have a confidential conversation about your market access needs.